Australia's Neuren Pharmaceuticals drops as US partner seeks EMA re-examination

Neuren Pharmaceuticals

03/03/2026 03:53

** Shares of Neuren Pharmaceuticals NEU.AX fall 8% to A$12.67, on track for their weakest session since February 5

** The biopharma firm says its partner, Acadia Pharmaceuticals ACAD.O, confirms plan to request re-examination of opinion adopted by Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA)

** Re-examination regarding the marketing of trofinetide for the treatment of Rett syndrome in patients two years and older - co

** Australian healthcare stocks .AXHJ down 1.5%, in line with broader benchmark .AXJO which is down 1.2%

** YTD, stock down 31.9%, including the day's move

 (Reporting by Sherin Sunny in Bengaluru)

 ((Sherin.Sunny@thomsonreuters.com))